Member Info for Dibs61

Hi unv, I feel like I am struggling to find you and the other band of long time regulars here! Erm tricky to tell whether some trades are buys/sells in a fast moving market. If I’m keen to know I normally try a dummy trade and I can tell from that, but not always. But it matters not at the end if the day as long as the SP is rising and boy did it start rising this afternoon. That was something to behold.

Yes well you can see we have a lot of newbies here coming in from other Covid hot stocks esp NCYT. Welcome all.

To our nice quiet backwater BB upomega, unv, rivaldo etc

No pumpky but they do not need to be out to stop selling. The Oryx stake fluctuates as the manager likes to trade it where he can (this is ordinarily an illiquid stock).

So he is reducing at the moment but I think unlikely to sell out completely. And then he may turn buyer again, he did a couple of weeks ago. So don’t get too hung up on the 11 million.

It’s been nearly a week now since the initial announcement. No doubt work was being done even over the Easter weekend. It’s interesting that MMs are slamming the price this morning spiking down. I would not be surprised following the Abingdon manufacturing expansion news if we get an update tomorrow morning.

In the next update I suspect ODX may announce expanding their capacity (only 2 out of 3 units at Alva currently utilised) along with taking on additional resources.

Days or less rather than weeks pumpky

Pillar 3: Mass-antibody testing to help determine if people have immunity to coronavirus
1.20 Antibody tests could tell people whether they have had the virus and are now immune. Such tests are done by taking a blood sample and looking for the presence of the right COVID-19 antibodies. Once proven in a laboratory setting, this testing could potentially be done at home with a finger prick and deliver rapid results - maybe in as little as twenty minutes.
11
COVID-19 - Scaling up our testing programmes
1.21 These antibody tests are brand new. In fact, they are still being developed and there is not yet one that has been proven to work as we would require. No government in the world has yet rolled out a full COVID-19 antibody testing programme.
1.22 We are currently engaged with several companies and are urgently testing the quality, accuracy and effectiveness of potential tests with scientific experts and regulators. We have bought some antibody testing kit stock on the basis of minimum initial volumes to enable clinical testing. If the outcome of this is that the antibody tests do not work, no further tests will be purchased and, where possible, orders will be cancelled.
1.23 Our experts are clear that an unreliable test is worse than no test. We need to be led by the evidence. Hence, the Chief Medical Officer discourages in the strongest terms organisations from buying their own unvalidated antibody tests.
1.24 Should our clinical testing prove successful, we hope to deploy antibody testing kits in their millions. In time, and subject to clinical advice, they could even be used to inform the use of social distancing measures in the future. However, this is some way off. In the meantime, we will keep the public updated on progress.

https://www.med-technews.com/news/four-institutions-form-uk-rapid-test-consortium/

Certainly has to be a buy and printed without delay. I think that this went through without budging the price just emphasises that our sellers order(s) is not yet filled. I think it will be immediately apparent when it finally has because this is not generally such a liquid stock. So, once they are gone liquidity will drop and normal demand and supply will resume. That’s my thinking anyway.

Happy with todays steady solid rise. Another 12.5% today will do nicely. I've now more than bagged here but not selling a bean.

Expecting a Holdings RNS or two to drop in the next day or so which should clarify who has been lightening their position.

We may see something of a repeat of Thursday with an initial spike as the pent up demand over long weekend, with all the publicity, is spent out. Perhaps to 30p. Then we’ll probably see a retrace back down to mid twenties with our seller back, hopefully to finish their selling tomorrow.

Probably has been quite a few stale bulls here too tbf.

So I think we’ll finish tomorrow somewhere in the mid twenties.

From thereonin who knows?

hi Bunsen - basically ODX are Part of UK backed consortium inc world class experts at Oxford Univ to develop a rapid point of care Covid 19 antibody Test. Check out last thursdays RNS. The company is also, unlike other Covid stocks, EBITDA positive revenue earning and has other highly promising strings to its bow. It is not expensive indeed it is cheap. There are institutions on the share register and one particular top performing fund manager Richard Sneller of Baillie Gifford has taken 25% of the company entirely with his own cash - very unusual. It has been off the radar still relatively speaking but has received media publicity over the weekend in the Daily Telegraph
, The Times, Metro etc.

But best suggestion is DYOR and you will see the investment case for yourself

Article contd

“We all have the research and development capability but also clearly we have the ability to manufacture at scale,” says Omega chief executive Colin King. “If we’re involved in the development process, it helps when it comes to manufacturing because you know what’s coming down the track.”

The current plan from the Government is, if this test is successful and is found to be as accurate as it needs to be, that it will be open standard.

“On this lateral flow stuff, I think we’re ahead of other countries. But we’re not being territorial about it and we’re not being too officious about it,” says Sir John. “We just want to make sure there’s a test which is feasible.”

Getting to this stage will not necessarily be quick or easy. For one thing, many in the sector are struggling with a lack of blood samples to use to develop their tests, and then check they're correct.

In any case, experts say, it will likely be a couple of weeks until the UK knows if the tests being developed now will be successful, and after that there will be more work in making sure, when manufacturing is scaled up, that quality can be maintained.

Right now, for a wider roll-out of the tests, “I’d say a couple of months is probably a reasonable time,” Sir John says. This may seem a long way away for many people. But Britain is a lot closer to a solution than it was two weeks ago.

There are some which Sir John says are closer to achieving this than others. One consortium which experts are particularly optimistic about is a group of life sciences companies which are based in England, Wales, Northern Ireland and Scotland respectively.

Abingdon Health, BBI Solutions, CIGA Healthcare and Omega Diagnostics on Wednesday evening announced they were working with Oxford University on developing an antibody test, and had received government funding to do so.

As well as pooling their expertise in developing such tests, the companies are hoping to use their manufacturing capacity, across the UK, to ramp up production quickly.

Just one of them on their own could make as many as 100,000 tests per week, so the potential is huge, although it will likely take at least a few months to get to that stage. TBC

Very encouraging article I’ve copied and pasted from The Daily Telegraph..quoting Colin King directly:

The UK biotech firms racing to create an antibody test
Earlier this week, the Government called on British businesses to join a 'national effort' to find a reliable antibody test
By
Hannah Boland
9 April 2020 • 5:06pm

Abingdon Health, BBI Solutions, CIGA Healthcare and Omega Diagnostics on Wednesday evening announced they were working with Oxford University on developing an antibody test CREDIT: The Telegraph/The Telegraph
It was the announcement that many healthcare workers had been waiting to hear: 3.5 million new antibody tests had been ordered and would be arriving “very soon”.

“It really matters for getting people getting back to work,” Health Secretary Matt Han**** said during the daily press briefing on March 24.

Unlike existing coronavirus tests, antibody tests would be able to tell if people had previously had the virus, he said, and so could potentially offer a way out of the lockdown. A week later, the number ordered ballooned to 17.5 million.

But, now, weeks later, the UK is still without any such test. The Government is said to be seeking a refund for kit from Chinese manufacturers which were found to be too unreliable.

The ones which have already been tested by scientists either “don’t give you the sensitivity or specificity that we would like,” Sir John Bell, Regius Professor of Medicine at Oxford University, explains. Ultimately, the truth is “they don’t work very well”.

The Government is now urgently trying to find better, more accurate tests. This week, on a call with industry, Han**** urged British life sciences and biotech businesses to join in a “national” effort to find a reliable antibody test.

It is a call many in the field are eager to answer.

Businesses across the country have already been working on producing what are known as lateral flow tests for the past few weeks, where people prick their finger and can get a result on whether they have had the virus within 15 minutes in a similar way to a pregnancy test.

In fact, there are those, including HIV-test maker BioSure, which have been growing increasingly frustrated on why they have not yet heard back from the Government on whether their test can be rolled out more widely.

In a video posted on Twitter last week, Brigette Bard said: “We are ready to go with validation of this test, but they won’t look at it. This test needs to be in the UK market.”

But, so far, says Sir John, those that had been looked at, and tested by researchers at the University of Oxford, were “a long way from where we need to be”.

“We’ve told them that we’re not being critical, we’re just saying keep going guys. You need a better test.”

Specifications were released earlier this week and, Bard admits, it is a very high bar.

TBC

This is from the UK governments own five pillar strategy:

‘In the meantime, we will keep the public updated on progress.’

This will be extremely high profile in the media. There won’t be any need to worry about publicity or mass public awareness.

This is very high stakes stuff and a successful lockdown exit stands or falls on this pillar - antibody testing. Get this right and the ODX SP literally goes to the moon. Critically though, as LT shareholders, and I have a low average here, the insurance policy for us is that even if this fails we are already a successful business with other potentially very lucrative products such as Food Detective and Visitect CD4. ODX is most certainly NOT a one trick pony.

Very important -DYOR

https://www.abingdonhealth.com/abingdon-health-key-partner-in-consortium-to-develop-a-uk-antibody-test/

https://www.scotsman.com/health/coronavirus/coronavirus-scots-life-sciences-firm-omega-help-make-kits-test-covid-19-immunity-2534220

Analysts at FinnCap said: “The market opportunity for cost-effective, high-volume antibody test is significant.”

Well that's something of an understatement if ever I heard one!

What new arrivals and people not yet invested here may not be aware that this is already a revenue generating EBITDA positive company even before today’s announcement.

It’s crucial you research the other substantial potential here over and above today’s huge news.

Market valuation still just a mere £29.5m. I think we’ve got a lot further to go once we get this sell order(s)completed. It’s completely feasible that the Food Intolerance division on its own is worth that much! Which means Visitect and the potential value of Covid Antibodies isn’t even in the price yet.

HEADLINE

ODX are directly involved in the governments UK RTC (Rapid Test Consortium) to develop and manufacture an antibody Test for COVID 19.

https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/ODX/14497652.html

https://www.heraldscotland.com/business_hq/18355469.scottish-biotech-firms-shares-jump-20-china-food-allergy-test-approved/